Weighted Average Number of Shares Outstanding, Basic of Xenon Pharmaceuticals Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Xenon Pharmaceuticals Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Xenon Pharmaceuticals Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 79,253,751, a 1.7% increase year-over-year.
  • Xenon Pharmaceuticals Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 79,253,751, a 1.7% increase from 2024.
  • Xenon Pharmaceuticals Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 77,894,643, a 16% increase from 2023.
  • Xenon Pharmaceuticals Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 66,889,005, a 10% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Xenon Pharmaceuticals Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 79,253,751 +1,359,108 +1.7% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 79,247,976 +1,321,771 +1.7% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 78,953,445 +1,282,317 +1.7% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 78,687,503 +1,092,904 +1.4% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 77,894,643 +11,005,638 +16% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 77,926,205 +11,924,042 +18% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 77,671,128 +11,809,990 +18% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 77,594,599 +11,869,918 +18% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 66,889,005 +6,346,863 +10% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 66,002,163 +537,094 +0.82% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 65,861,138 +9,668,216 +17% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 65,724,681 +10,871,889 +20% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 60,542,142 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 65,465,069 +23,190,721 +55% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 56,192,922 +14,102,715 +34% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 54,852,792 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q3 2021 42,274,348 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 42,090,207 +7,110,925 +20% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q2 2020 34,979,282 +9,205,403 +36% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q2 2019 25,773,879 +11,467,388 +80% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 25,753,836 +7,949,415 +45% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 19,425,711 +1,440,650 +8% 01 Oct 2018 31 Dec 2018 10-K 06 Mar 2019 2018 FY
Q3 2018 20,306,298 +2,307,878 +13% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2018 2018 Q3
Q2 2018 14,306,491 -3,690,703 -21% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 17,804,421 -141,788 -0.79% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 17,985,061 +2,491,587 +16% 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
Q3 2017 17,998,420 +2,729,456 +18% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 17,997,194 +3,589,086 +25% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 17,946,209 +3,552,209 +25% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 15,493,474 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2018 2017 FY
Q3 2016 15,268,964 +970,352 +6.8% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 14,408,108 +166,281 +1.2% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 14,394,000 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q3 2015 14,298,612 +12,950,195 +960% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2015 2015 Q3
Q2 2015 14,241,827 +12,894,590 +957% 01 Apr 2015 30 Jun 2015 10-Q 03 Aug 2016 2016 Q2
Q3 2014 1,348,417 +11,389 +0.85% 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015 2015 Q3
Q2 2014 1,347,237 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q3 2013 1,337,028 01 Jul 2013 30 Sep 2013 10-Q 15 Dec 2014 2014 Q3

Xenon Pharmaceuticals Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 79,253,751 +1,359,108 +1.7% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 77,894,643 +11,005,638 +16% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 66,889,005 +6,346,863 +10% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 60,542,142 +16,914,690 +39% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 43,627,452 +9,085,239 +26% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 34,542,213 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2018 19,425,711 +1,440,650 +8% 01 Jan 2018 31 Dec 2018 10-K 06 Mar 2019 2018 FY
2017 17,985,061 +2,491,587 +16% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
2016 15,493,474 +1,211,637 +8.5% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2018 2017 FY
2015 14,281,837 +11,116,265 +351% 01 Jan 2015 31 Dec 2015 10-K 07 Mar 2018 2017 FY
2014 3,165,572 +1,827,910 +137% 01 Jan 2014 31 Dec 2014 10-K 08 Mar 2017 2016 FY
2013 1,337,662 +10,202 +0.77% 01 Jan 2013 31 Dec 2013 10-K 08 Mar 2016 2015 FY
2012 1,327,460 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.